Clinical Rheumatology

, Volume 26, Issue 10, pp 1693–1700

Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience

  • Liisa Konttinen
  • Riitta Tuompo
  • Tea Uusitalo
  • Riitta Luosujärvi
  • Kari Laiho
  • Jukka Lähteenmäki
  • Maija Puurtinen-Vilkki
  • Ritva Lanteri
  • Saara Kortelainen
  • Helena Karilainen
  • Tuire Varjolahti-Lehtinen
  • Dan Nordström
Original Article

Abstract

Biological therapy for ankylosing spondylitis (AS) has led to improved disease control beyond that of conventional treatments. International recommendations encourage clinicians prescribing biological treatments to register patients in national registers to collect information on outcome and toxicity. Patients with AS (n = 229) from the Register of Biological Treatment in Finland (ROB-FIN) with severe disease of long duration were followed-up for up to 24 months. Due to an active disease, one or more concomitant disease-modifying antirheumatic drugs (DMARDs) were used by 86% at commencement of biological therapy. This add-on strategy with infliximab led to a rapid pain relief and improvement of patient’s and physician’s global assessments, C-reactive protein/erythrocyte sedimentation rate, and swollen and tender joint counts within 6 weeks. Concomitant use of NSAID and oral corticosteroid was reduced. Corresponding results were documented at 3 months with etanercept, which was more recently approved for the treatment of spondyloarthropathies. Seventy-nine percent of the patients were ASAS 20 responders. A subgroup of AS patients with only axial involvement (n = 46) responded correspondingly. The first biological drug was discontinued in only 7% due to lack of efficacy and in 6% due to adverse events. Anti-TNF agents, often used in combination with DMARDs, appeared to have persistent effectiveness and limited toxicity in a real-life clinical setting in a cohort of Finnish AS patients with severe disease and long disease duration.

Keywords

Ankylosing spondylitis Biologicals Combination therapy 

References

  1. 1.
    Braun J, Sieper J (2002) Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches. Arthritis Res 4:307–321PubMedCrossRefGoogle Scholar
  2. 2.
    Boulos P, Dougados M, MacLeod SM et al (2005) Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65:2111–2127PubMedCrossRefGoogle Scholar
  3. 3.
    Zochling J, Braun J (2005) Management and treatment of ankylosing spondylitis. Curr Opin Rheumatol 17:418–425PubMedCrossRefGoogle Scholar
  4. 4.
    Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193PubMedCrossRefGoogle Scholar
  5. 5.
    Davis JC Jr, van der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230–3236PubMedCrossRefGoogle Scholar
  6. 6.
    Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600PubMedCrossRefGoogle Scholar
  7. 7.
    Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575PubMedCrossRefGoogle Scholar
  8. 8.
    van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591PubMedCrossRefGoogle Scholar
  9. 9.
    Braun J, Pham T, Sieper J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824PubMedCrossRefGoogle Scholar
  10. 10.
    Braun J, Davis J, Dougados M et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316–320PubMedCrossRefGoogle Scholar
  11. 11.
    Konttinen L, Honkanen V, Uotila T et al (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916–922PubMedCrossRefGoogle Scholar
  12. 12.
    Konttinen L, Kankaanpaa E, Luosujarvi R et al (2006) Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin Rheumatol 25:882–884PubMedCrossRefGoogle Scholar
  13. 13.
    Nordstrom DC, Konttinen L, Korpela M et al (2006) Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. Rheumatol Int26:741–748PubMedCrossRefGoogle Scholar
  14. 14.
    Zochling J, Bohl-Bühler MHJ, Baraliakos X et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25:794–800PubMedCrossRefGoogle Scholar
  15. 15.
    Breban M, Vignon E, Claudepierre P et al (2002) Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41:1280–1285PubMedCrossRefGoogle Scholar
  16. 16.
    Temekonidis TI, Alamanos Y, Nikas SN et al (2003) Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 62:1218–1220PubMedCrossRefGoogle Scholar
  17. 17.
    Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959–965PubMedGoogle Scholar
  18. 18.
    Braun J, Baraliakos X, Brandt J et al (2005) Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34:178–190PubMedCrossRefGoogle Scholar
  19. 19.
    Mottonen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 353:1568–1573PubMedCrossRefGoogle Scholar
  20. 20.
    Wagner CL, Schantz A, Barnathan E et al (2003) Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol 112:37–53Google Scholar
  21. 21.
    Altan L, Bingol U, Karakoc Y et al (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30:255–259PubMedCrossRefGoogle Scholar
  22. 22.
    Roychowdhury B, Bintley-Bagot S, Bulgen DY et al (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41:1330–1332PubMedCrossRefGoogle Scholar
  23. 23.
    Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31:1568–1574PubMedGoogle Scholar
  24. 24.
    Pham T, Landewe R, van der Linden S et al (2006) An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 65:1620–1625PubMedCrossRefGoogle Scholar
  25. 25.
    Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42:2325–2329PubMedCrossRefGoogle Scholar
  26. 26.
    Keystone EC (2003) Advances in targeted therapy: safety of biological agents. Ann Rheum Dis 62:ii34–ii36PubMedCrossRefGoogle Scholar
  27. 27.
    Haraoui B, Keystone E (2006) Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 18:96–100PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  • Liisa Konttinen
    • 1
  • Riitta Tuompo
    • 2
  • Tea Uusitalo
    • 2
  • Riitta Luosujärvi
    • 2
    • 3
  • Kari Laiho
    • 4
    • 10
  • Jukka Lähteenmäki
    • 5
  • Maija Puurtinen-Vilkki
    • 6
  • Ritva Lanteri
    • 7
  • Saara Kortelainen
    • 3
  • Helena Karilainen
    • 8
  • Tuire Varjolahti-Lehtinen
    • 9
  • Dan Nordström
    • 1
    • 2
  1. 1.University of HelsinkiHelsinkiFinland
  2. 2.Division of Medicine and RheumatologyHelsinki University Central HospitalHelsinkiFinland
  3. 3.Kuopio University HospitalKuopioFinland
  4. 4.Rheumatism Foundation HospitalHeinolaFinland
  5. 5.Joensuu Central HospitalJoensuuFinland
  6. 6.Turku University Central HospitalTurkuFinland
  7. 7.Seinäjoki Central HospitalSeinäjokiFinland
  8. 8.Rauma HospitalRaumaFinland
  9. 9.Tampere University HospitalTampereFinland
  10. 10.Department of Musculoskeletal Medicine, Medical SchoolUniversity of TampereTampereFinland

Personalised recommendations